Late-stage pipeline products can generate demand in the MG market and with diagnosed prevalent cases, will drive growth in ...

An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...

AstraZeneca’s rare disease business, Alexion, has partnered with British health tech Pangaea Data to fund the startup’s ...

ALEXION PHARMACEUTICALS, INC.'s most active month to dispose stocks was the month of June. 2020 saw ALEXION PHARMACEUTICALS, INC. paying a total of $0.00 for 1,109,910 shares, ...

Alexion Pharmaceuticals (ALXN) came out with quarterly earnings of $3.52 per share, beating the Zacks Consensus Estimate of $3.08 per share. This compares to earnings of $3.22 per share a year ago.

Late last week, AstraZeneca said that it would acquire Alexion Pharmaceuticals ALXN - a company that is best known for its Soliris and Ultomiris drugs which are used to treat rare blood disorders ...

Alexion Pharmaceuticals, Inc.'s (NASDAQ:ALXN) price-to-earnings (or "P/E") ratio of 56.5x might make it look like a strong sell right now compared to the market in the United States, where around ...

Alexion Pharmaceuticals is being acquired by AstraZeneca, company officials announced on Saturday. The deal is worth $39 billion, the Associated Press reported. The boards of directors of both ...

An icon in the shape of a lightning bolt. Impact Link AstraZeneca on Saturday announced it was acquiring Alexion Pharmaceuticals for $39 billion, a deal aimed at boosting AstraZeneca's immunology ...

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) just released its quarterly report and things are looking bullish. Alexion Pharmaceuticals delivered a significant beat to revenue and earnings per ...